NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Showcase DERMAdoctor’s Eczema Balm on Return QVC® Appearance

By September 12, 2022

Calm Cool + Corrected Eczema + Dermatitis Clinical Repair Balm to be Featured on “Girls’ Night In with Courtney & Jane” on September 13 at 9 p.m. Eastern Time

 EMERYVILLE, Calif. (September 12, 2022)NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that Chief Product Officer Audrey Kunin, MD will return to the QVC network for her third on-air appearance this year to discuss DERMAdoctor’s revolutionary Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm. This problem-solving eczema treatment will be featured on “Girls’ Night In with Courtney & Jane” on Tuesday, September 13 at 9 p.m. Eastern time.

“It’s particularly timely to highlight Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm’s significant benefits just weeks before the October 1st start of National Eczema Awareness Month,” said Dr. Kunin. “Eczema often flares with seasonal changes and our Calm Cool + Corrected Eczema balm provides temporary relief of minor irritations and itching, while maximizing hydration to calm and soothe affected skin. Importantly, our balm is gentle enough to be used anywhere eczema appears on the body. It is one of the many DERMAdoctor products we created to provide real solutions for real people with real skin concerns.”

Eczema affects an estimated 31 million Americans. Although it is typically thought to be a childhood condition, more than 16 million U.S. adults are afflicted by eczema, according to the Asthma and Allergy Foundation of America. Atopic dermatitis, the most common form of eczema, is a chronic, inflammatory skin disease that results in widespread rashes and patches of itchy skin. Those afflicted report lifestyle limitations that affect their daily activities and cause them to avoid social interactions.

Dr. Kunin is a board-certified dermatologist, author, clinician, educator, television personality and recognized trailblazer in the skincare industry. She founded DERMAdoctor to deliver on the promise that clinical skin therapy can be simple and easy. DERMAdoctor products are scientifically formulated to provide measurable results for common skincare concerns that have been overlooked by the beauty industry.

Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm incorporates a special form of eczema-active 1% colloidal oatmeal with enhanced beta glucan, an advanced complex of ceramides and essential lipids, and dermatologic botanicals. Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm has received the National Eczema Association (NEA) Seal of Acceptance, which is granted in recognition of products that meet the NEA’s rigorous standards for providing benefits and improving the quality of life for people with eczema and sensitive skin.

About NovaBay Pharmaceuticals, Inc:
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells scientifically created and clinically proven consumer products for the eyecare and skincare markets. Avenova® is the most prescribed antimicrobial lid and lash spray and DERMAdoctor® is a premium skincare brand offering more than 30 dermatologist-developed skincare products sold through traditional domestic retailers, digital beauty channels and international distributors.

NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, current product offerings, marketing efforts, and any future revenue that may result from selling such products, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the integration of DERMAdoctor’s business into the Company’s business, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, and revenues will not be sufficient to meet the Company’s cash needs. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay Informed on NovaBays Progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website

Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email

DERMAdoctor Purchasing Information
For DERMAdoctor purchasing information:
Please call 877-337-6237 or email

NovaBay Contact
Justin Hall
Chief Executive Officer and General Counsel

Investor Contact
LHA Investor Relations
Jody Cain